{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-040779","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.172762+00:00","generated_at":"2026-05-24T14:13:30.650424+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Coya Therapeutics FY2024 net loss $14.9M; cash $38.3M; pipeline updates for ALS and FTD trials","bullets":["Net loss $14.9M in 2024 vs $8.0M in 2023; R&D expenses $11.9M (up from $5.5M).","Cash and equivalents $38.3M as of Dec 31, 2024; raised $10M private placement and $5M from ADDF.","Received $3.85M from Dr. Reddy's for COYA-302 ALS Phase 2; eligible for additional $8.4M milestone.","Plan to submit nonclinical data to FDA in Q2 2025 for COYA-302 ALS Phase 2b trial initiation.","Expect to file IND for COYA-302 Phase 2b in FTD in 2H 2025; top-line data from investigator trial also in 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-040779","json":"https://secwatch.observer/filing/0000950170-25-040779.json","markdown":"https://secwatch.observer/filing/0000950170-25-040779.md","text":"https://secwatch.observer/filing/0000950170-25-040779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017025040779/0000950170-25-040779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017025040779/coya-20250318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:13:30.650424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}